Skip to main content
TipRanks
Go Ultimate75% OFF

Vivoryon Therapeutics AG (05Y) Q2 2025 Earnings Report

40 Followers

DE:05Y Q2 2025 EPS Results

Actual EPS
-EUR 0.21
Consensus EPS
―
Beat/Miss
―
One Year Ago EPS
-EUR 0.63

DE:05Y Q2 2025 Revenue Results

Actual Revenue
EUR 0
Expected Revenue
―
Beat/Miss
―
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q2 2025
Date
09/04/2025
Time
Before Open
Conference Call
Thursday, September 4, 2025
DE:05Y Upcoming Earnings

Vivoryon Therapeutics AG's next earnings date is estimated for April 29, 2027, based on past reporting schedules.

Q2 2025 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q2 2025 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2025 Earnings Call Summary

Q2 2025
Earnings Call Date:Sep 04, 2025|% Change Since:-57.50%|
Earnings Call Sentiment|Neutral

The earnings call highlighted significant clinical and financial progress, particularly in reducing expenses and advancing the varoglutamstat program, while also addressing challenges such as a reduced cash position and the need for additional financing for future studies.

Company Guidance

In the recent call discussing Vivoryon's first half 2025 results, several key metrics and achievements were highlighted. Research and development expenses for the period were EUR 2.8 million, a significant reduction from EUR 10.3 million in the first half of 2024, primarily due to decreased clinical development costs and production expenses. General and administrative expenses also saw a decline to EUR 2.8 million from EUR 3.5 million in the previous year. Consequently, the net loss for the first half of 2025 was reduced to EUR 5.5 million, compared to EUR 13.6 million in the same period of 2024. The company reported holding EUR 4.8 million in cash and cash equivalents as of June 30, 2025, with a cash runway extending into January 2026, excluding funds from a standby equity purchase agreement. Vivoryon also secured U.S. patents for varoglutamstat, ensuring market exclusivity through 2044. The company presented compelling kidney function data from its Phase II studies at the European Renal Association Annual Congress, showcasing statistically significant improvements in kidney function with varoglutamstat compared to placebo. Preparations for a dedicated Phase IIb study in diabetic kidney disease are underway, highlighting Vivoryon's strategic focus on expanding its therapeutic impact in the kidney disease market.

  • Significant Reduction in R&D ExpensesResearch and development expenses decreased by EUR 7.5 million, from EUR 10.3 million in the first half of 2024 to EUR 2.8 million in the first half of 2025, largely due to a decrease in clinical development and production costs.
  • Net Loss ReductionThe company reported a net loss of EUR 5.5 million for the first half of 2025, compared to EUR 13.6 million for the first half of 2024, indicating improved financial management.
  • Strong Clinical Data for VaroglutamstatVaroglutamstat demonstrated statistically significant and clinically meaningful improvements in kidney functions in Phase II studies, with notable benefits in diabetic kidney disease patients.
  • New U.S. Patent for VaroglutamstatVivoryon secured a new U.S. composition of matter patent for varoglutamstat, supporting market exclusivity through 2044 with potential for extension.
  • Preclinical Success in Diabetic Kidney Disease ModelVaroglutamstat showed impressive reductions in inflammation and fibrosis in a diabetic kidney disease mouse model.
  • Positive Feedback from Scientific CommunityThe data presented at the European Renal Association Annual Congress and ASN Kidney Week were well received by the nephrology community, increasing interest in varoglutamstat.

DE:05Y Earnings History

DE:05Y earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Apr 29, 20272026 (Q4)―--0.12――
Nov 05, 20262026 (Q3)―--0.21―
Aug 06, 20262026 (Q2)―-0.11-0.2145.71% (+0.10)
Jun 11, 20262026 (Q1)―--0.27―
Apr 23, 20262025 (Q4)―-0.12-0.2756.13% (+0.15)
Dec 04, 20252025 (Q3)―--0.52―
Sep 04, 20252025 (Q2)―-0.21-0.6366.67% (+0.42)
Jun 17, 20252025 (Q1)―--0.68―
Apr 29, 20252024 (Q4)―-0.27-0.6860.21% (+0.41)
Dec 10, 20242024 (Q3)―--0.41―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed